Human hepatocytes derived from pluripotent stem cells: a promising cell model for drug hepatotoxicity screening

Archives of Toxicology

Volumn 90, Issue 9, 2016, Pages 2049-2061

  Gómez Lechón, María José ^a,b   Tolosa, Laia ^a  

^a INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL CLÍNICO SAN CARLOS IDISSC   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Embryonic stem cells; Hepatocyte like cells; Hepatotoxicity; Induced pluripotent stem cells; Pluripotent stem cells; Screening

Indexed keywords

DRUG;

CELL DIFFERENTIATION; CRYOPRESERVATION; DRUG SCREENING; EMBRYONIC STEM CELL; HIGH THROUGHPUT SCREENING; HUMAN; INDUCED PLURIPOTENT STEM CELL; LIVER CELL; LIVER TOXICITY; MOLECULAR STABILITY; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; STEM CELL EXPANSION; TOXIC HEPATITIS; TOXICITY TESTING; ANIMAL; ANIMAL TESTING ALTERNATIVE; BIOASSAY; CELL CULTURE; CELL LINEAGE; CELL PROLIFERATION; CHEMICAL AND DRUG INDUCED LIVER INJURY; DRUG EFFECTS; LIVER; METABOLISM; PATHOLOGY; PHENOTYPE; PROCEDURES; RISK ASSESSMENT;

ANIMAL TESTING ALTERNATIVES; ANIMALS; BIOLOGICAL ASSAY; CELL DIFFERENTIATION; CELL LINEAGE; CELL PROLIFERATION; CELLS, CULTURED; CHEMICAL AND DRUG INDUCED LIVER INJURY; HEPATOCYTES; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LIVER; PHENOTYPE; RISK ASSESSMENT; TOXICITY TESTS;

EID: 84975263417     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-016-1756-1     Document Type: Review

References (78)

1. Alexopoulos LG, Saez-Rodriguez J, Cosgrove BD, Lauffenburger DA, Sorger PK (2010) Networks inferred from biochemical data reveal profound differences in toll-like receptor and inflammatory signaling between normal and transformed hepatocytes. Mol Cell Proteomics 9(9):1849–1865. doi:10.1074/mcp.M110.000406
2. Anson BD, Kolaja KL, Kamp TJ (2011) Opportunities for use of human iPS cells in predictive toxicology. Clin Pharmacol Ther 89(5):754–758
3. Antherieu S, Chesne C, Li R, Guguen-Guillouzo C, Guillouzo A (2012) Optimization of the HepaRG cell model for drug metabolism and toxicity studies. Toxicol In Vitro 26(8):1278–1285. doi:10.1016/j.tiv.2012.05.008
4. Asplund A, Pradip A, van Giezen M et al (2016) One standardized differentiation procedure robustly generates homogenous hepatocyte cultures displaying metabolic diversity from a large panel of human pluripotent stem cells. Stem Cell Rev 12(1):90–104. doi:10.1007/s12015-015-9621-9
5. Baxter MA et al (2010) Generating hepatic cell lineages from pluripotent stem cells for drug toxicity screening. Stem Cell Res 5(1):4–22
6. Baxter M et al (2015) Phenotypic and functional analyses show stem cell-derived hepatocyte-like cells better mimic fetal rather than adult hepatocytes. J Hepatol 62(3):581–589
7. Berger DR, Ware BR, Davidson MD, Allsup SR, Khetani SR (2015) Enhancing the functional maturity of induced pluripotent stem cell-derived human hepatocytes by controlled presentation of cell-cell interactions in vitro. Hepatology 61(4):1370–1381. doi:10.1002/hep.27621
8. Bjornsson ES (2015) Drug-induced liver injury: an overview over the most critical compounds. Arch Toxicol 89(3):327–334. doi:10.1007/s00204-015-1456-2
9. Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S (2013) Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 144(7):1419–1425
10. Brolen G et al (2010) Hepatocyte-like cells derived from human embryonic stem cells specifically via definitive endoderm and a progenitor stage. J Biotechnol 145(3):284–294
11. Cameron K, Tan R, Schmidt-Heck W et al (2015) Recombinant laminins drive the differentiation and self-organization of hESC-derived hepatocytes. Stem Cell Reports 5(6):1250–1262. doi:10.1016/j.stemcr.2015.10.016
12. Chen YF, Tseng CY, Wang HW, Kuo HC, Yang VW, Lee OK (2012) Rapid generation of mature hepatocyte-like cells from human induced pluripotent stem cells by an efficient three-step protocol. Hepatology 55(4):1193–1203. doi:10.1002/hep.24790
13. Davidson MD, Ware BR, Khetani SR (2015) Stem cell-derived liver cells for drug testing and disease modeling. Discov Med 19(106):349–358
14. Dianat N, Steichen C, Vallier L, Weber A, Dubart-Kupperschmitt A (2013) Human pluripotent stem cells for modelling human liver diseases and cell therapy. Curr Gene Ther 13(2):120–132
15. Donato MT, Jover R, Gomez-Lechon MJ (2013) Hepatic cell lines for drug hepatotoxicity testing: limitations and strategies to upgrade their metabolic competence by gene engineering. Curr Drug Metab 14(9):946–968
16. Du Y et al (2014) Human hepatocytes with drug metabolic function induced from fibroblasts by lineage reprogramming. Cell Stem Cell 14(3):394–403
17. Gieseck RL 3rd et al (2014) Maturation of induced pluripotent stem cell derived hepatocytes by 3D-culture. PLoS One 9(1):e86372. doi:10.1371/journal.pone.0086372
18. Giobbe GG, Michielin F, Luni C et al (2015) Functional differentiation of human pluripotent stem cells on a chip. Nat Methods 12(7):637–640. doi:10.1038/nmeth.3411
19. Godoy P et al (2013) Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol 87(8):1315–1530. doi:10.1007/s00204-013-1078-5
20. Gomez-Lechon MJ, Donato MT, Castell JV, Jover R (2004) Human hepatocytes in primary culture: the choice to investigate drug metabolism in man. Curr Drug Metab 5(5):443–462
21. Gomez-Lechon MJ, Castell JV, Donato MT (2008) An update on metabolism studies using human hepatocytes in primary culture. Expert Opin Drug Metab Toxicol 4(7):837–854. doi:10.1517/17425255.4.7.837
22. Gomez-Lechon MJ, Tolosa L, Conde I, Donato MT (2014) Competency of different cell models to predict human hepatotoxic drugs. Expert Opin Drug Metab Toxicol 10(11):1553–1568. doi:10.1517/17425255.2014.967680
23. Grimm FA, Iwata Y, Sirenko O, Bittner M, Rusyn I (2015) High-content assay multiplexing for toxicity screening in induced pluripotent stem cell-derived cardiomyocytes and hepatocytes. Assay Drug Dev Technol 13(9):529–546. doi:10.1089/adt.2015.659
24. Hannan NR, Segeritz CP, Touboul T, Vallier L (2013) Production of hepatocyte-like cells from human pluripotent stem cells. Nat Protoc 8(2):430–437
25. Hay DC et al (2008) Highly efficient differentiation of hESCs to functional hepatic endoderm requires ActivinA and Wnt3a signaling. Proc Natl Acad Sci USA 105(34):12301–12306
26. Hay DC et al (2011) Unbiased screening of polymer libraries to define novel substrates for functional hepatocytes with inducible drug metabolism. Stem Cell Res 6(2):92–102
27. Hewitt NJ et al (2007) Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 39(1):159–234
28. Holmgren G et al (2014) Long-term chronic toxicity testing using human pluripotent stem cell-derived hepatocytes. Drug Metab Dispos 42(9):1401–1406
29. Huang P et al (2014) Direct reprogramming of human fibroblasts to functional and expandable hepatocytes. Cell Stem Cell 14(3):370–384
30. Katsuda T, Sakai Y, Ochiya T (2012) Induced pluripotent stem cell-derived hepatocytes as an alternative to human adult hepatocytes. J Stem Cells 7(1):1–17
31. Kia R, Sison RL, Heslop J et al (2013) Stem cell-derived hepatocytes as a predictive model for drug-induced liver injury: are we there yet? Br J Clin Pharmacol 75(4):885–896. doi:10.1111/j.1365-2125.2012.04360.x
32. Kia R, Kelly L, Sison-Young RL et al (2015) MicroRNA-122: a novel hepatocyte-enriched in vitro marker of drug-induced cellular toxicity. Toxicol Sci 144(1):173–185. doi:10.1093/toxsci/kfu269
33. Kim JH, Jang YJ, An SY et al (2015) Enhanced metabolizing activity of human ES cell-derived hepatocytes using a 3D culture system with repeated exposures to xenobiotics. Toxicol Sci 147(1):190–206. doi:10.1093/toxsci/kfv121
34. Klein M, Thomas M, Hofmann U, Seehofer D, Damm G, Zanger UM (2015) A systematic comparison of the impact of inflammatory signaling on absorption, distribution, metabolism, and excretion gene expression and activity in primary human hepatocytes and HepaRG cells. Drug Metab Dispos 43(2):273–283. doi:10.1124/dmd.114.060962
35. Kondo Y et al (2014) An efficient method for differentiation of human induced pluripotent stem cells into hepatocyte-like cells retaining drug metabolizing activity. Drug Metab Pharmacokinet 29(3):237–243
36. Li S et al (2015) Valproic acid-induced hepatotoxicity in Alpers syndrome is associated with mitochondrial permeability transition pore opening-dependent apoptotic sensitivity in an induced pluripotent stem cell model. Hepatology 61(5):1730–1739. doi:10.1002/hep.27712
37. Lu J, Einhorn S, Venkatarangan L et al (2015) Morphological and functional characterization and assessment of iPSC-derived hepatocytes for in vitro toxicity testing. Toxicol Sci 147(1):39–54. doi:10.1093/toxsci/kfv117
38. Mandenius CF et al (2011) Toward preclinical predictive drug testing for metabolism and hepatotoxicity by using in vitro models derived from human embryonic stem cells and human cell lines-a report on the Vitrocellomics EU-project. Altern Lab Anim 39(2):147–171
39. Mann DA (2015) Human induced pluripotent stem cell-derived hepatocytes for toxicology testing. Expert Opin Drug Metab Toxicol 11(1):1–5. doi:10.1517/17425255.2015.981523
40. McGivern JV, Ebert AD (2014) Exploiting pluripotent stem cell technology for drug discovery, screening, safety, and toxicology assessments. Adv Drug Deliv Rev 69–70:170–178
41. Medine CN, Lucendo-Villarin B, Storck C et al (2013) Developing high-fidelity hepatotoxicity models from pluripotent stem cells. Stem Cells Transl Med 2(7):505–509. doi:10.5966/sctm.2012-0138
42. Mueller D, Kramer L, Hoffmann E, Klein S, Noor F (2014) 3D organotypic HepaRG cultures as in vitro model for acute and repeated dose toxicity studies. Toxicol In Vitro 28(1):104–112. doi:10.1016/j.tiv.2013.06.024
43. Nakamura N, Saeki K, Mitsumoto M et al (2012) Feeder-free and serum-free production of hepatocytes, cholangiocytes, and their proliferating progenitors from human pluripotent stem cells: application to liver-specific functional and cytotoxic assays. Cell Reprogram 14(2):171–185. doi:10.1089/cell.2011.0064
44. Norris W, Paredes AH, Lewis JH (2008) Drug-induced liver injury in 2007. Curr Opin Gastroenterol 24(3):287–297. doi:10.1097/MOG.0b013e3282f9764b00001574-200805000-00005
45. O’Brien PJ, Chan K, Silber PM (2004) Human and animal hepatocytes in vitro with extrapolation in vivo. Chem Biol Interact 150(1):97–114
46. Park BK, Laverty H, Srivastava A, Antoine DJ, Naisbitt D, Williams DP (2011) Drug bioactivation and protein adduct formation in the pathogenesis of drug-induced toxicity. Chem Biol Interact 192(1–2):30–36
47. Rashid ST et al (2010) Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest 120(9):3127–3136
48. Roberts M et al (2014) The global intellectual property landscape of induced pluripotent stem cell technologies. Nat Biotechnol 32(8):742–748
49. Saez-Rodriguez J, Alexopoulos LG, Zhang M, Morris MK, Lauffenburger DA, Sorger PK (2011) Comparing signaling networks between normal and transformed hepatocytes using discrete logical models. Cancer Res 71(16):5400–5411. doi:10.1158/0008-5472.CAN-10-4453
50. Schwartz RE, Fleming HE, Khetani SR, Bhatia SN (2014) Pluripotent stem cell-derived hepatocyte-like cells. Biotechnol Adv 32(2):504–513
51. Sengupta S, Johnson BP, Swanson SA, Stewart R, Bradfield CA, Thomson JA (2014) Aggregate culture of human embryonic stem cell-derived hepatocytes in suspension are an improved in vitro model for drug metabolism and toxicity testing. Toxicol Sci 140(1):236–245
52. Simeonov KP, Uppal H (2014) Direct reprogramming of human fibroblasts to hepatocyte-like cells by synthetic modified mRNAs. PLoS One 9(6):e100134. doi:10.1371/journal.pone.0100134
53. Sirenko O, Hesley J, Rusyn I, Cromwell EF (2014) High-content assays for hepatotoxicity using induced pluripotent stem cell-derived cells. Assay Drug Dev Technol 12(1):43–54. doi:10.1089/adt.2013.520
54. Si-Tayeb K et al (2010) Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. Hepatology 51(1):297–305. doi:10.1002/hep.23354
55. Sivertsson L, Synnergren J, Jensen J, Bjorquist P, Ingelman-Sundberg M (2013) Hepatic differentiation and maturation of human embryonic stem cells cultured in a perfused three-dimensional bioreactor. Stem Cells Dev 22(4):581–594. doi:10.1089/scd.2012.0202
56. Sjogren AK, Liljevald M, Glinghammar B et al (2014) Critical differences in toxicity mechanisms in induced pluripotent stem cell-derived hepatocytes, hepatic cell lines and primary hepatocytes. Arch Toxicol 88(7):1427–1437. doi:10.1007/s00204-014-1265-z
57. Soldatow VY, Lecluyse EL, Griffith LG, Rusyn I (2013) Models for liver toxicity testing. Toxicol Res (Camb) 2(1):23–39. doi:10.1039/C2TX20051A
58. Song Z et al (2009) Efficient generation of hepatocyte-like cells from human induced pluripotent stem cells. Cell Res 19(11):1233–1242
59. Stine JG, Lewis JH (2011) Drug-induced liver injury: a summary of recent advances. Expert Opin Drug Metab Toxicol 7(7):875–890. doi:10.1517/17425255.2011.577415
60. Subba Rao M, Sasikala M, Nageshwar Reddy D (2013) Thinking outside the liver: induced pluripotent stem cells for hepatic applications. World J Gastroenterol 19(22):3385–3396. doi:10.3748/wjg.v19.i22.3385
61. Subramanian K et al (2014) Spheroid culture for enhanced differentiation of human embryonic stem cells to hepatocyte-like cells. Stem Cells Dev 23(2):124–131. doi:10.1089/scd.2013.0097
62. Szkolnicka D, Farnworth SL, Lucendo-Villarin B, Hay DC (2014) Deriving functional hepatocytes from pluripotent stem cells. Curr Protoc Stem Cell Biol 30:1G–5. doi:10.1002/9780470151808.sc01g05s30
63. Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4):663–676
64. Takayama K, Inamura M, Kawabata K et al (2012) Efficient generation of functional hepatocytes from human embryonic stem cells and induced pluripotent stem cells by HNF4alpha transduction. Mol Ther 20(1):127–137. doi:10.1038/mt.2011.234
65. Takayama K et al (2013) 3D spheroid culture of hESC/hiPSC-derived hepatocyte-like cells for drug toxicity testing. Biomaterials 34(7):1781–1789
66. Takayama K et al (2014) Prediction of interindividual differences in hepatic functions and drug sensitivity by using human iPS-derived hepatocytes. Proc Natl Acad Sci USA 111(47):16772–16777
67. Tasnim F, Phan D, Toh YC, Yu H (2015) Cost-effective differentiation of hepatocyte-like cells from human pluripotent stem cells using small molecules. Biomaterials 70:115–125. doi:10.1016/j.biomaterials.2015.08.002
68. Terry C, Dhawan A, Mitry RR, Lehec SC, Hughes RD (2010) Optimization of the cryopreservation and thawing protocol for human hepatocytes for use in cell transplantation. Liver Transpl 16(2):229–237. doi:10.1002/lt.21983
69. Tolosa L, Caron J, Hannoun Z et al (2015) Transplantation of hESC-derived hepatocytes protects mice from liver injury. Stem Cell Res Ther 6(1):246. doi:10.1186/s13287-015-0227-6
70. Touboul T et al (2010) Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development. Hepatology 51(5):1754–1765. doi:10.1002/hep.23506
71. Ulvestad M et al (2013) Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells. Biochem Pharmacol 86(5):691–702
72. Vinoth KJ et al (2014) Evaluation of human embryonic stem cells and their differentiated fibroblastic progenies as cellular models for in vitro genotoxicity screening. J Biotechnol 184:154–168
73. Vunjak-Novakovic G, Bhatia S, Chen C, Hirschi K (2013) HeLiVa platform: integrated heart–liver–vascular systems for drug testing in human health and disease. Stem Cell Res Ther 4(Suppl 1):S8. doi:10.1186/scrt369
74. Ware BR, Berger DR, Khetani SR (2015) Prediction of drug-induced liver injury in micropatterned co-cultures containing iPSC-derived human hepatocytes. Toxicol Sci 145(2):252–262
75. Wobus AM, Boheler KR (2005) Embryonic stem cells: prospects for developmental biology and cell therapy. Physiol Rev 85(2):635–678
76. Yao R et al (2014) Hepatic differentiation of human embryonic stem cells as microscaled multilayered colonies leading to enhanced homogeneity and maturation. Small 10(21):4311–4323. doi:10.1002/smll.201401040
77. Yi F, Liu GH, Izpisua Belmonte JC (2012) Human induced pluripotent stem cells derived hepatocytes: rising promise for disease modeling, drug development and cell therapy. Protein Cell 3(4):246–250. doi:10.1007/s13238-012-2918-4
78. Yildirimman R et al (2011) Human embryonic stem cell derived hepatocyte-like cells as a tool for in vitro hazard assessment of chemical carcinogenicity. Toxicol Sci 124(2):278–290